Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas

Trial Profile

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Aug 2019 Planned End Date changed from 1 Nov 2018 to 1 Aug 2023.
    • 04 Dec 2018 Preliminary results assessing evaluating clinicopathologic diagnosis compared to gene expression in B cell lymhoma patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=33) assessing tolerability of brentuximab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone in patients with CD30 positive primary mediastinal large B-cell lymphoma, CD30 positive diffuse large B-cell lymphoma or CD30 positive grey zone lymphoma, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top